Stock PHAR PHARMING GROUP N.V.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Pharming Group N.V. Nasdaq

Equities

PHAR

US71716E1055

Market Closed - Nasdaq
Other stock markets
 02:00:00 15/06/2024 am IST 		5-day change 1st Jan Change
8.6 USD +0.04% Intraday chart for Pharming Group N.V. +1.90% -24.76%
31/05 Pharming Group Flags Delay in EU Review of Rare Immunodeficiency Drug MT
30/05 Pharming Group N.V. Provides Update on Ongoing Regulatory Review of Leniolisib for the Treatment of Apds in the European Union CI

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 55% by 2026.
  • The company is in a robust financial situation considering its net cash and margin position.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Analyst opinion has improved significantly over the past four months.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company sustains low margins.
  • The company is highly valued given the cash flows generated by its activity.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
PHARMING GROUP N.V. Stock Pharming Group N.V.
-24.76% 535M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+50.70% 791B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+41.96% 630B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.15% 350B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.77% 328B
B-
ABBVIE INC. Stock AbbVie Inc.
+8.79% 298B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.02% 246B
B+
ROCHE HOLDING AG Stock Roche Holding AG
+1.27% 225B
A+
NOVARTIS AG Stock Novartis AG
+11.95% 218B
B-
AMGEN INC. Stock Amgen Inc.
+3.68% 160B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. PHARM Stock
  4. PHAR Stock
  5. Ratings Pharming Group N.V.